SEC Form PREM14C filed by Apimeds Pharmaceuticals US Inc.
$APUS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds Pharmaceuticals US Inc. (NYSE:APUS) and Mindwave Innovations Inc. The merger brings together a biotech development platform with an AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment, for which E.F. Hutton acted as Placement Agent. E.F. Hutton's involvement underscores its commitment to advancing the combined company's strategic growth across late-stage biotech development and institutional Digital Asset Treasury Solutions. E.F. Hutton worked closely with both companies to shape the transaction fram
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company's financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones. The financing also facilitates the integration of MindWave Innovations Inc., aligning corporate operations and financial management processes. As part of that integration, approximately 1,000 Bitcoin previously held by MindWave have been transferred into a segregated, risk-managed structure. This digital-asset position is governed under a defined inv
SCHEDULE 13G - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)
PREM14C - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)